KV10.1 | EAG1 | Eag Related Potassium Channel Member 1
Family:
Potassium channels
Subgroups:
Shaker (KV1.1–KV1.8), Shab (KV2.1-KV2.2), Shaw (KV3.1–KV3.4), Shal (KV4.1–KV4.3), KQT like (KV7.1–KV7.5), Eag related (KV10.1-KV10.2), Erg related (KV11.1–KV11.3), Elk related (KV12.1)
Topology:
Contains six transmembrane domains (S1–S6), four single subunits form a pore, homotetramers and heterotetramers are possible.
KV10.1 Background Information
KV10.1, also known as human ether à-go-go1 protein or EAG1, is the pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel. Upon a depolarization, a slowly activating noninactivating outward current is elicited. Upon repolarization a small tail current occurs. EAG1 is expressed almost exclusively in brain tissue and is involved in cell excitability, memory processes, and cell proliferation. Their expression in over 70% of human tumours makes them an attractive diagnostic and therapeutic target treatment of prostate cancer: The Eag1 K+ channel is especially thought to be involved in the pathophysiological processes of prostate cancer, and is expected to be a valuable target for the diagnosis and treatment of prostate cancer.
Gene:
KCNH1
Human Protein:
O95259
Tissue:
Brain (cortex, hippocampus, caudate, putamen, amygdala and weakly in substantia nigra, retina), kidney, lung, pancreas, bone marrow mesenchymal stem cells, heart
Function/ Application:
Cell proliferation, cell excitability, transformation of epithelial cells, mediates IKNI current in myoblasts
Pathology:
Cancer, Temple-Baraitser Syndrome, Zimmermann-Laband Syndrome 1, myasthenic syndrome, congenital 5 , acute contagious conjunctivitis
Interaction:
KV2.1, epsin, KCR1, ICA, KV10.2, ALG10B, CaM, slop, RABEP1, CTTN
Modulator:
Quinidine, astemizole, E-4031, terfenadine, dofetilide, haloperidol, imipramine,
Assays:
Patch Clamp: whole cell, state- and use-dependance, temperature control
Recommended Reviews:
Gutman et al. (2005) International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 57(4):473-508